Efficacy of a high quality O1/Campos foot-and-mouth disease vaccine upon challenge with a heterologous Korean O Mya98 lineage virus in pigs

Novo, Sabrina Galdo; Malirat, Viviana; Maradei, Eduardo; Pedemonte, Andrea; Espinoza, Ana Maria; Smitsaart, Eliana; Lee, K.N.; Park, J.H.; Bergmann, I

doi:10.1016/j.vaccine.2018.02.015

Cited by 15 publications

(8 citation statements)

References 32 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The O1 Campos strain was selected for this study because it conforms to the antigen banks that are used in case of FMDV outbreaks around the world (Galdo Novo et al., 2018) and because it is one of the strains used for the PPG test in Argentina.…”

Section: Methodsmentioning

confidence: 99%

“…The O1 Campos strain was selected for this study because it conforms to the antigen banks that are used in case of FMDV outbreaks around the world (Galdo Novo et al, 2018) and because it is one of the strains used for the PPG test in Argentina. FMDV O1 Campos was kindly provided by Biogenesis Bagó S.A. as a binary ethylene-imine (BEI)-inactivated virus suspension (iFMDV).…”

Section: Virusmentioning

confidence: 99%

See 1 more Smart Citation

Mouse model as an efficacy test for foot‐and‐mouth disease vaccines

Gnazzo

Quattrocchi

Soria

et al. 2020

Transbound. Emerg. Dis.

View full text Add to dashboard Cite

Foot-and-mouth disease virus (FMDV) is a picornavirus belonging to the Aphthovirus genus (Soria et al., 2017). FMDV has seven distinct serotypes, namely O, A, C, SAT1, SAT2, SAT3 and Asia 1. This virus produces foot-and-mouth disease (FMD), a devastating and highly transmissible infection of farm animals, with large associated economic losses. Some countries are either FMD free or close to achieving eradication, while others are at an early stage of FMD control. In many countries, FMD control is performed by regular vaccination based on inactivated whole virus (Soria et al., 2017).

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Virusmentioning

confidence: 99%

Mouse model as an efficacy test for foot‐and‐mouth disease vaccines

Gnazzo

Quattrocchi

Soria

et al. 2020

Transbound. Emerg. Dis.

View full text Add to dashboard Cite

show abstract

“…However, FMD was prevalent until 2016, and another large-scale FMD outbreak occurred in 2014–2015 ( 9 – 14 ) which prompted the introduction of diverse serotype O vaccine strains besides O1 Manisa. In 2017, a comprehensive biannual vaccination program for cattle and goats and post-vaccination sero-monitoring, in addition to year-round serosurveillance, were launched ( 10 , 11 , 15 ). The current vaccination regimen was adopted after the serotype A FMD outbreak in porcine in the spring of 2018.…”

Section: Introductionmentioning

confidence: 99%

Post-vaccination Monitoring to Assess Foot-and-Mouth Disease Immunity at Population Level in Korea

et al. 2021

View full text Add to dashboard Cite

In South Korea, domestic cattle, pigs, and goats were subjected to mandatory foot-and-mouth disease (FMD) vaccination and year-round serosurveillance since 2011. In 2020, approximately USD 95 million was spent solely for FMD vaccine purchase for 59 million livestock, and 1.25 million samples were tested to estimate the population immunity and demonstrate the absence of virus circulation. As the FMD vaccination program was revised in 2018, the post-vaccination monitoring (PVM) was designed to evaluate the effectiveness of the vaccine program of three vaccines approved for routine use. To this end, monitoring post-vaccination immunity has been conducted by collecting 35,626 serum samples at 28 days post-vaccination following regular national vaccinations, which were carried out in April and in October in 2020. The design of the serological test for PVM was specially targeted at particular livestock groups, including dairy cattle, goats, and beef cattle aged 6–12 months, which were generally estimated to have a low expected seroprevalence. The risk factors had also been identified, considering the increased likelihood of infection in a particular location, herd size, and husbandry system applied in a targeted sample collection. Serum sample collection and SP-O and NSP antibody tests were performed by local veterinary laboratories using commercially available ELISAs. The current FMD vaccination program, which was performed twice a year following the regimen of primary vaccination and boost, resulted in over 80% population immunity. The seroprevalence monitored after the vaccination in fall was higher than the one studied in spring except in pigs. It was demonstrated that the seroprevalence of risk-based targeted samples ranged from 93.8 to 100% in cattle, 63.2 to 100% in pigs, and 20.0 to 100% in goats. Of note is the area near the North Korean borders which showed a relatively low seroprevalence among the targeted regions, and no NSP sero-positive reactor was detected in this region. When subpopulation immunity at the individual level was assessed, the seroprevalence in young cattle stock was slightly lower (95.8%) than that of adults (98.4%). In conclusion, the FMD vaccination campaign has been successfully implemented in Korea, and the PVM can be a supplementary program for massive routine surveillance in terms of providing timely information needed both to estimate population immunity and to properly target “risk-based surveillance.”

show abstract

“…However, this clear separation of the serological relationship was not shown by the r 1 -values of group B-B. According to other studies, the r 1 -value determined using higher titers of sera would be lower than that determined using lower titers of sera [ 17 ], and r 1 -values for the pool of pig sera tended to be higher than those for the cattle pool [ 18 ]. Therefore, this unclear distinction in the serological relationship in the r 1 -values of group B-B might be explained by the relatively large portion of low-titer porcine sera in group B-B.…”

Section: Discussionmentioning

confidence: 80%

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs

et al. 2023

View full text Add to dashboard Cite

Three commercial vaccines are administered in domestic livestock farms for routine vaccination to aid for foot-and-mouth disease (FMD) control in Korea. Each vaccine contains distinct combinations of inactivated serotype O and A FMD virus (FMDV) antigens: O/Manisa + O/3039 + A/Iraq formulated in a double oil emulsion (DOE), O/Primorsky + A/Zabaikalsky formulated in a DOE, and O/Campos + A/Cruzeiro + A/2001 formulated in a single oil emulsion. Despite the recommendation for a prime-boost vaccination with the same vaccine in fattening pigs, occasional cross-inoculation is inevitable for many reasons, such as lack of compliance with vaccination guidelines, erroneous application, or change in vaccine types by suppliers. Therefore, there have been concerns that a poor immune response could be induced by cross-inoculation due to a failure to boost the immune response. In the present study, it was demonstrated by virus neutralization and ELISA tests that cross-inoculation of pigs with three commercial FMD vaccines does not hamper the immune response against the primary vaccine strains and enhances broader cross-reactivity against heterologous vaccine antigens whether they were applied or not. Therefore, it could be concluded that the cross-inoculation of FMD vaccines can be used as a regimen to strategically overcome the limitation of the antigenic spectrum induced by the original regimen.

show abstract

Efficacy of a high quality O1/Campos foot-and-mouth disease vaccine upon challenge with a heterologous Korean O Mya98 lineage virus in pigs

Cited by 15 publications

References 32 publications

Mouse model as an efficacy test for foot‐and‐mouth disease vaccines

Mouse model as an efficacy test for foot‐and‐mouth disease vaccines

Post-vaccination Monitoring to Assess Foot-and-Mouth Disease Immunity at Population Level in Korea

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs

Contact Info

Product

Resources

About